List of insiders holdings for Dyne Therapeutics Inc.:
- Shares directly owned by the insider.
- Shares indirectly owned by the insider.
- Total shares owned by the insider (sum of shares directly and indirectly owned).
- Total market value if available.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| # | Insider Holder Name | Report Date Time |
Shares Owned Directly Indirectly |
Total Shares Owned |
Filing |
| 1 | Rhodes Jason P Director |
2025-01-29 16:15:05 | 0 9,130,465 |
9,130,465 | Form 4 |
| 2 | RA CAPITAL MANAGEMENT L.P. Kolchinsky Peter Shah Rajeev M. 10% Owner |
2024-11-14 17:46:12 | 6,381,144 0 |
6,381,144 | Form 13G |
| 3 | Forbion Capital Fund IV Cooperatief U.A. 10% Owner |
2024-11-14 07:00:28 | 5,795,364 0 |
5,795,364 | Form 13G |
| 4 | Atlas Venture Fund XI L.P. Atlas Venture Associates XI L.P. Atlas Venture Associates XI LLC Atlas Venture Opportunity Fund I L.P. Atlas Venture Associates Opportunity I L.P. Atlas Venture Associates Opportunity I LLC Atlas Venture Opportunity Fund II L.P. Atlas Venture Associates Opportunity II LP Atlas Venture Associates Opportunity II LLC 10% Owner |
2024-11-14 16:32:40 | 5,714,057 0 |
5,714,057 | Form 13G |
| 5 | Kersten Dirk Director |
2024-12-10 16:05:03 | 0 5,462,846 |
5,462,846 | Form 4 |
| 6 | MPM BIOVENTURES 2018 L.P. MPM BIOVENTURES 2018 (B) L.P. MPM ASSET MANAGEMENT INVESTORS BV2018 LLC MPM BioVentures 2018 GP LLC MPM BioVentures 2018 LLC EVNIN LUKE Foley Todd GADICKE ANSBERT 10% Owner |
2024-02-12 16:06:32 | 3,451,303 0 |
3,451,303 | Form 13G |
| 7 | Atlas Venture Opportunity Fund I L.P. Atlas Venture Associates Opportunity I L.P. Atlas Venture Associates Opportunity I LLC Atlas Venture Opportunity Fund II L.P. Atlas Venture Associates Opportunity II LP Atlas Venture Associates Opportunity II LLC 10% Owner |
2024-03-05 17:07:00 | 1,458,691 847,388 |
2,306,079 | Form 4 |
| 8 | VV Manager II LLC Vida Ventures II LLC VIDA VENTURES II-A LLC 10% Owner |
2023-02-10 16:31:31 | 2,220,034 0 |
2,220,034 | Form 13D |
| 9 | Logos Global Management LP 10% Owner |
2023-02-14 15:53:47 | 2,150,000 0 |
2,150,000 | Form 13G |
| 10 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% Owner |
2020-09-23 18:56:45 | 1,608,785 0 |
1,608,785 | Form 4 |
| 11 | Brumm Joshua T CEO & President |
2024-03-12 21:56:20 | 754,536 0 |
754,536 | Form 4 |
| 12 | Subramanian Romesh Chief Scientific Officer 10% Owner |
2020-09-18 17:12:38 | 694,434 0 |
694,434 | Form 4 |
| 13 | CureDuchenne Ventures LLC 10% Owner |
2020-09-23 19:05:52 | 602,972 0 |
602,972 | Form 4 |
| 14 | Lucera Erick Chief Financial Officer |
2025-04-01 16:33:30 | 280,600 0 |
280,600 | Form 4 |
| 15 | Beskrovnaya Oxana Chief Scientific Officer |
2025-03-13 16:08:14 | 195,840 0 |
195,840 | Form 4 |
| 16 | Cox John CEO & President |
2025-03-07 16:07:03 | 146,239 32,000 |
178,239 | Form 4 |
| 17 | Farwell Wildon Chief Medical Officer |
2024-08-20 16:27:16 | 143,222 0 |
143,222 | Form 4 |
| 18 | McNeill Jonathan Chief Business Officer |
2024-08-20 16:27:39 | 132,106 0 |
132,106 | Form 4 |
| 19 | HIGH SUSANNA GATTI Chief Operating Officer |
2024-09-19 16:52:28 | 131,636 0 |
131,636 | Form 4 |
| 20 | Scalzo Richard William SVP, Head of Finance & Admin. |
2025-03-13 16:08:57 | 122,330 0 |
122,330 | Form 4 |
| 21 | Friedl-Naderer Johanna Chief Commercial Officer |
2025-03-13 16:13:26 | 96,057 0 |
96,057 | Form 4 |
| 22 | Kerr Douglas Chief Medical Officer |
2025-03-07 16:08:14 | 94,157 0 |
94,157 | Form 4 |
| 23 | Stehman-Breen Catherine Director |
2024-05-24 17:10:26 | 25,133 0 |
25,133 | Form 4 |
| 24 | HURWITZ EDWARD Director |
2024-05-24 17:10:17 | 25,133 0 |
25,133 | Form 4 |
| 25 | Lubner David Charles Director |
2024-05-24 17:10:09 | 25,133 0 |
25,133 | Form 4 |
| 26 | Incerti Carlo Director |
2024-11-18 19:42:09 | 22,693 0 |
22,693 | Form 4 |
| 27 | Klein Lawrence Otto Director |
2022-07-06 18:20:16 | 7,222 0 |
7,222 | Form 4 |